glp-1 origin Timeline of discovery and clinical development. (a) Key events in Glucagon-like peptide 1 (GLP-1) -
Description
This study showed that the median time to onset of the overall GLP-1 RA-related AEs was 31 days (IQR = 7145.4 days), which varied among GLP-1 RA regimens
Gastrointestinal Risks and Neutral Findings in Cancer and Immunity GLP-1RA use was not associated with overall cancer risk, and drug-specific analyses showed no significant associations
Cardiovascular risk management also appears to be gaining momentum as these agents are increasingly showing benefit in reducing the risk of major cardiovascular events
Has a fiduciary duty to act in the best interests of participants
